New drug cocktail aims to control rare blood cancer without chemo

NCT ID NCT03863184

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of three drugs—acalabrutinib, lenalidomide, and either rituximab or obinutuzumab—in people with untreated mantle cell lymphoma. The goal is to see how well the combo clears cancer cells from the blood and shrinks tumors. Participants receive the drugs for about a year, then continue on a maintenance schedule until the disease worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib, lenalidomide, and rituximab or obinutuzumab
What this could lead to: If successful, this combination could offer a more effective first-line treatment for mantle cell lymphoma, potentially leading to longer remission without the need for chemotherapy.
What could go wrong: This is a small, early-phase study (37 people) without a comparison group. The drugs have known side effects like low blood counts, infections, and fatigue. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.